Do analysts rate NUWE or TMDIF?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Titan Medical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, NUWE or TMDIF?

Titan Medical has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.27M 0.32 -$17.52M -$132.59 N/A Titan Medical $17.63M 0.85 $6.95M $0.05 2.64

Is NUWE or TMDIF more profitable?

Titan Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Titan Medical's return on equity of -82.31% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -623.14% -147.34% Titan Medical N/A -82.31% -51.47%

Do analysts prefer NUWE or IRIX?

IRIDEX has a consensus target price of $3.00, indicating a potential upside of 328.14%. Given IRIDEX's stronger consensus rating and higher probable upside, analysts plainly believe IRIDEX is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 IRIDEX 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, NUWE or IRIX?

IRIDEX has higher revenue and earnings than Nuwellis. IRIDEX is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuwellis $8.27M 0.32 -$17.52M -$132.59 N/A IRIDEX $52.67M 0.23 -$4.44M -$0.20 N/A

Is NUWE or IRIX more profitable?

IRIDEX has a net margin of -6.88% compared to Nuwellis' net margin of -123.38%. IRIDEX's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -623.14% -147.34% IRIDEX -6.88% N/A -12.55%

Do analysts prefer ADGM or NUWE?

Adagio Medical currently has a consensus price target of $3.50, indicating a potential upside of 547.31%. Given Adagio Medical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Adagio Medical is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adagio Medical 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings & valuation, ADGM or NUWE?

Nuwellis has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagio Medical $600K 20.01 -$25.08M -$1.48 N/A Nuwellis $8.27M 0.32 -$17.52M -$132.59 N/A

Is ADGM or NUWE more profitable?

Adagio Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Nuwellis' return on equity of -623.14% beat Adagio Medical's return on equity. Company Net Margins Return on Equity Return on Assets Adagio Medical N/A -661.85% -73.35% Nuwellis -123.38% -623.14% -147.34%

Do analysts prefer NUWE or HSCS?

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 138.10%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Nuwellis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 HeartSciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is NUWE or HSCS more profitable?

HeartSciences has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. HeartSciences' return on equity of -358.60% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -623.14% -147.34% HeartSciences N/A -358.60% -144.82%

Do analysts rate NUWE or MBAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nuwellis 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Check-Cap 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is NUWE or MBAI more profitable?

Check-Cap has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Check-Cap's return on equity of 0.00% beat Nuwellis' return on equity. Company Net Margins Return on Equity Return on Assets Nuwellis -123.38% -623.14% -147.34% Check-Cap N/A N/A N/A

Nuwellis (NUWE) Competitors

$0.73 0.00 (-0.58%)

As of 09/3/2026 04:00 PM Eastern

Compare

NUWE vs. TMDIF, IRIX, ADGM, HSCS, and MBAI

Should you buy Nuwellis stock or one of its competitors? Nuwellis's main competitors and comparable companies include Titan Medical (TMDIF), IRIDEX (IRIX), Adagio Medical (ADGM), HeartSciences (HSCS), and Check-Cap (MBAI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Nuwellis compare to Titan Medical?

Nuwellis (NASDAQ:NUWE) and Titan Medical (NASDAQ:TMDIF) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Titan Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Titan Medical's return on equity of -82.31% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
Titan Medical	N/A	-82.31%	-51.47%

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 0.0% of Titan Medical shares are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Comparatively, 0.0% of Titan Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Nuwellis' average media sentiment score of 0.76 beat Titan Medical's score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Overall Sentiment
Nuwellis	Positive
Titan Medical	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Titan Medical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Titan Medical has higher revenue and earnings than Nuwellis. Nuwellis is trading at a lower price-to-earnings ratio than Titan Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.32	-$17.52M	-$132.59	N/A
Titan Medical	$17.63M	0.85	$6.95M	$0.05	2.64

Nuwellis has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Titan Medical has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Summary

Titan Medical beats Nuwellis on 8 of the 13 factors compared between the two stocks.

How does Nuwellis compare to IRIDEX?

Nuwellis (NASDAQ:NUWE) and IRIDEX (NASDAQ:IRIX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

IRIDEX has a consensus target price of $3.00, indicating a potential upside of 328.14%. Given IRIDEX's stronger consensus rating and higher probable upside, analysts plainly believe IRIDEX is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
IRIDEX	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

IRIDEX has a net margin of -6.88% compared to Nuwellis' net margin of -123.38%. IRIDEX's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
IRIDEX	-6.88%	N/A	-12.55%

In the previous week, Nuwellis' average media sentiment score of 0.76 beat IRIDEX's score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Overall Sentiment
Nuwellis	Positive
IRIDEX	Neutral

IRIDEX has higher revenue and earnings than Nuwellis. IRIDEX is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.32	-$17.52M	-$132.59	N/A
IRIDEX	$52.67M	0.23	-$4.44M	-$0.20	N/A

3.1% of Nuwellis shares are owned by institutional investors. Comparatively, 20.1% of IRIDEX shares are owned by institutional investors. 1.6% of Nuwellis shares are owned by company insiders. Comparatively, 8.6% of IRIDEX shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Nuwellis has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, IRIDEX has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Summary

IRIDEX beats Nuwellis on 12 of the 15 factors compared between the two stocks.

How does Nuwellis compare to Adagio Medical?

Adagio Medical (NASDAQ:ADGM) and Nuwellis (NASDAQ:NUWE) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

In the previous week, Nuwellis' average media sentiment score of 0.76 beat Adagio Medical's score of 0.00 indicating that Nuwellis is being referred to more favorably in the news media.

Company	Overall Sentiment
Adagio Medical	Neutral
Nuwellis	Positive

Adagio Medical currently has a consensus price target of $3.50, indicating a potential upside of 547.31%. Given Adagio Medical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Adagio Medical is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Nuwellis has higher revenue and earnings than Adagio Medical. Adagio Medical is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagio Medical	$600K	20.01	-$25.08M	-$1.48	N/A
Nuwellis	$8.27M	0.32	-$17.52M	-$132.59	N/A

Adagio Medical has a beta of -0.09, indicating that its stock price is 109% less volatile than the broader market. Comparatively, Nuwellis has a beta of 0.23, indicating that its stock price is 77% less volatile than the broader market.

48.1% of Adagio Medical shares are held by institutional investors. Comparatively, 3.1% of Nuwellis shares are held by institutional investors. 7.8% of Adagio Medical shares are held by company insiders. Comparatively, 1.6% of Nuwellis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Adagio Medical has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Nuwellis' return on equity of -623.14% beat Adagio Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	-661.85%	-73.35%
Nuwellis	-123.38%	-623.14%	-147.34%

Summary

Adagio Medical beats Nuwellis on 9 of the 15 factors compared between the two stocks.

How does Nuwellis compare to HeartSciences?

Nuwellis (NASDAQ:NUWE) and HeartSciences (NASDAQ:HSCS) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

HeartSciences has lower revenue, but higher earnings than Nuwellis. HeartSciences is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.32	-$17.52M	-$132.59	N/A
HeartSciences	N/A	N/A	-$9.14M	-$3.94	N/A

HeartSciences has a consensus target price of $8.00, suggesting a potential upside of 138.10%. Given HeartSciences' stronger consensus rating and higher probable upside, analysts plainly believe HeartSciences is more favorable than Nuwellis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
HeartSciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, HeartSciences had 1 more articles in the media than Nuwellis. MarketBeat recorded 1 mentions for HeartSciences and 0 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.76 beat HeartSciences' score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Overall Sentiment
Nuwellis	Positive
HeartSciences	Neutral

HeartSciences has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. HeartSciences' return on equity of -358.60% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
HeartSciences	N/A	-358.60%	-144.82%

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 17.2% of HeartSciences shares are held by institutional investors. 1.6% of Nuwellis shares are held by company insiders. Comparatively, 4.9% of HeartSciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nuwellis has a beta of 0.23, suggesting that its share price is 77% less volatile than the broader market. Comparatively, HeartSciences has a beta of 1.85, suggesting that its share price is 85% more volatile than the broader market.

Summary

HeartSciences beats Nuwellis on 12 of the 15 factors compared between the two stocks.

How does Nuwellis compare to Check-Cap?

Nuwellis (NASDAQ:NUWE) and Check-Cap (NASDAQ:MBAI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.

Nuwellis has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Check-Cap has a beta of 0.67, meaning that its stock price is 33% less volatile than the broader market.

Check-Cap has lower revenue, but higher earnings than Nuwellis. Check-Cap is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuwellis	$8.27M	0.32	-$17.52M	-$132.59	N/A
Check-Cap	N/A	N/A	$4.14M	-$14.07	N/A

3.1% of Nuwellis shares are held by institutional investors. Comparatively, 1.1% of Check-Cap shares are held by institutional investors. 1.6% of Nuwellis shares are held by insiders. Comparatively, 0.5% of Check-Cap shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Check-Cap had 3 more articles in the media than Nuwellis. MarketBeat recorded 3 mentions for Check-Cap and 0 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.76 beat Check-Cap's score of 0.00 indicating that Nuwellis is being referred to more favorably in the media.

Company	Overall Sentiment
Nuwellis	Positive
Check-Cap	Neutral

Check-Cap has a net margin of 0.00% compared to Nuwellis' net margin of -123.38%. Check-Cap's return on equity of 0.00% beat Nuwellis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuwellis	-123.38%	-623.14%	-147.34%
Check-Cap	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuwellis	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Check-Cap	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Check-Cap beats Nuwellis on 7 of the 12 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NUWE vs. The Competition

Export

Metric	Nuwellis	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.70M	$5.81B	$7.26B	$12.73B
Dividend Yield	N/A	1.76%	2.53%	8.86%
P/E Ratio	-0.01	25.93	273.28	25.38
Price / Sales	0.32	73.29	613.48	92.60
Price / Cash	N/A	33.14	77.82	52.26
Price / Book	-1.31	6.04	12.89	6.14
Net Income	-$17.52M	$150.03M	$3.47B	$349.01M
7 Day Performance	-17.35%	-1.30%	0.61%	-0.27%
1 Month Performance	-60.92%	1.29%	5.73%	0.68%
1 Year Performance	-99.57%	9.89%	25.37%	14.84%

Nuwellis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NUWE Nuwellis	0.7366 of 5 stars	$0.73 -0.6%	N/A	-99.6%	$2.70M	$8.27M	N/A	70
TMDIF Titan Medical	N/A	$0.12 -2.3%	N/A	-60.8%	$13.19M	$17.63M	N/A	50
IRIX IRIDEX	1.6289 of 5 stars	$0.71 -1.2%	$3.00 +324.1%	-49.4%	$12.58M	$52.67M	N/A	120
ADGM Adagio Medical	1.7297 of 5 stars	$0.52 -5.1%	$3.50 +570.5%	-66.9%	$12.22M	$600K	N/A	87
HSCS HeartSciences	2.1585 of 5 stars	$2.99 -0.3%	$8.00 +167.6%	-2.3%	$11.70M	N/A	N/A	10	Upcoming Earnings Short Interest Decrease Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NUWE) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Nuwellis (NUWE) Competitors

NUWE vs. TMDIF, IRIX, ADGM, HSCS, and MBAI

How does Nuwellis compare to Titan Medical?

Summary

How does Nuwellis compare to IRIDEX?

Summary

How does Nuwellis compare to Adagio Medical?

Summary

How does Nuwellis compare to HeartSciences?

Summary

How does Nuwellis compare to Check-Cap?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Nuwellis (NUWE) Competitors

NUWE vs. TMDIF, IRIX, ADGM, HSCS, and MBAI

How does Nuwellis compare to Titan Medical?

Is NUWE or TMDIF more profitable?

Do institutionals & insiders hold more shares of NUWE or TMDIF?

Does the media prefer NUWE or TMDIF?

Do analysts rate NUWE or TMDIF?

Which has preferable valuation & earnings, NUWE or TMDIF?

Which has more risk and volatility, NUWE or TMDIF?

Summary

How does Nuwellis compare to IRIDEX?

Do analysts prefer NUWE or IRIX?

Is NUWE or IRIX more profitable?

Does the media prefer NUWE or IRIX?

Which has stronger earnings and valuation, NUWE or IRIX?

Do institutionals and insiders believe in NUWE or IRIX?

Which has more risk and volatility, NUWE or IRIX?

Summary

How does Nuwellis compare to Adagio Medical?

Does the media refer more to ADGM or NUWE?

Do analysts prefer ADGM or NUWE?

Which has preferable earnings & valuation, ADGM or NUWE?

Which has more volatility and risk, ADGM or NUWE?

Do insiders and institutionals have more ownership in ADGM or NUWE?

Is ADGM or NUWE more profitable?

Summary

How does Nuwellis compare to HeartSciences?

Which has higher earnings and valuation, NUWE or HSCS?

Do analysts prefer NUWE or HSCS?

Does the media prefer NUWE or HSCS?

Is NUWE or HSCS more profitable?

Do institutionals & insiders have more ownership in NUWE or HSCS?

Which has more risk & volatility, NUWE or HSCS?

Summary

How does Nuwellis compare to Check-Cap?

Which has more risk and volatility, NUWE or MBAI?

Which has preferable valuation and earnings, NUWE or MBAI?

Do institutionals and insiders have more ownership in NUWE or MBAI?

Does the media prefer NUWE or MBAI?

Is NUWE or MBAI more profitable?

Do analysts rate NUWE or MBAI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NUWE vs. The Competition

Nuwellis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools